Omeros (OMER) Cost of Revenue (2015 - 2026)
Omeros recorded quarterly Cost of Revenue of $587000.0 in Q1 2026, down 98.02% quarter-over-quarter from $29.7 million in Q4 2021.
Omeros' Cost of Revenue history runs 8 years deep, the most recent figure standing at $587000.0 for Q1 2026.
- In Q1 2026, Cost of Revenue changed N/A year-over-year to $587000.0; the TTM figure through Mar 2026 stood at $30.6 million (up 0.81% YoY), while the FY2021 annual figure was $30.6 million, up 3295.9% from the prior year.
- Cost of Revenue came in at $587000.0 for Q1 2026 at Omeros, down from $29.7 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $587000.0 in Q1 2026 to a low of $587000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 587,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 587,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Dec 31, 2021 | 29.69 Mn |
| Dec 31, 2021 | 29.69 Mn |
| Sep 30, 2021 | 333,000.00 |
| Sep 30, 2021 | 333,000.00 |
| Jun 30, 2021 | 342,000.00 |
| Jun 30, 2021 | 342,000.00 |
| Mar 31, 2021 | 263,000.00 |
| Mar 31, 2021 | 263,000.00 |
| Dec 31, 2020 | 87,000.00 |
| Dec 31, 2020 | 87,000.00 |
| Sep 30, 2020 | 401,000.00 |
| Sep 30, 2020 | 401,000.00 |
| Jun 30, 2020 | 147,000.00 |
| Jun 30, 2020 | 147,000.00 |
| Mar 31, 2020 | 267,000.00 |
| Mar 31, 2020 | 267,000.00 |
| Dec 31, 2019 | 401,000.00 |
| Dec 31, 2019 | 401,000.00 |
| Sep 30, 2019 | 278,000.00 |
| Sep 30, 2019 | 278,000.00 |
| Jun 30, 2019 | 55,000.00 |
| Jun 30, 2019 | 55,000.00 |
| Mar 31, 2019 | 131,000.00 |
| Mar 31, 2019 | 131,000.00 |
| Dec 31, 2018 | 157,000.00 |
| Dec 31, 2018 | 157,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 116,000.00 |
| Jun 30, 2018 | 116,000.00 |
| Mar 31, 2018 | 203,000.00 |
| Mar 31, 2018 | 203,000.00 |
| Dec 31, 2017 | 465,000.00 |
| Dec 31, 2017 | 465,000.00 |
| Sep 30, 2017 | 184,000.00 |
| Sep 30, 2017 | 184,000.00 |
| Jun 30, 2017 | 157,000.00 |
| Jun 30, 2017 | 157,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Dec 31, 2016 | 380,000.00 |
| Dec 31, 2016 | 380,000.00 |
| Sep 30, 2016 | 378,000.00 |
| Sep 30, 2016 | 378,000.00 |
| Jun 30, 2016 | 327,000.00 |
| Jun 30, 2016 | 327,000.00 |
| Mar 31, 2016 | 327,000.00 |
| Mar 31, 2016 | 327,000.00 |
| Dec 31, 2015 | 417,000.00 |
| Dec 31, 2015 | 417,000.00 |
| Sep 30, 2015 | 248,000.00 |
| Sep 30, 2015 | 248,000.00 |
| Jun 30, 2015 | 365,000.00 |
| Jun 30, 2015 | 365,000.00 |
| Mar 31, 2015 | 11,000.00 |
| Mar 31, 2015 | 11,000.00 |